Used as a key intermediate in the synthesis of tyrosine kinase inhibitors, particularly in targeted cancer therapies. It plays a role in the development of pharmaceuticals that inhibit abnormal protein signaling in tumor cells, especially in treatments for chronic myeloid leukemia (CML) and non-small cell lung cancer (NSCLC). Its structure enables strong binding to specific kinase domains, enhancing the selectivity and efficacy of the drug while minimizing off-target effects. Also investigated for use in next-generation anticancer agents due to its stability and ability to cross cell membranes effectively.